The Business of Fashion
Agenda-setting intelligence, analysis and advice for the global fashion community.
Agenda-setting intelligence, analysis and advice for the global fashion community.
New York, United States — Estée Lauder Cos. rose in early trading after online sales and a push deeper into China helped maintain its growth streak.
The New York-based seller of Clinique and Aveda products saw sales surge across most of its brands in the latest quarter, with skin care, makeup and fragrances all posting double-digit gains. Online sales — an area of increasing importance for cosmetics companies — also rose.
“In the holiday season, our brands achieved outstanding results from their e-commerce businesses, and customisable gift options were significant contributors,” said chief executive Fabrizio Freda in a statement.
Estée Lauder has profited from higher demand for fragrances and premium cosmetics and capitalised on a growing Chinese market, helping it outpace rivals and reward investors. Its acquisition of Millennial-friendly brands and quick adaptation of digital technology to boost online sales have helped sales accelerate for five straight quarters.
ADVERTISEMENT
The shares rose as much as 3 percent to $138.55 in early trading. The stock has gained almost 70 percent in the last 12 months.
Excluding some items, profit was $1.52 a share, surpassing the average estimate of $1.44 from analysts. Sales of $3.74 billion also exceeded the estimate of $3.67 billion.
The results sparked more optimistic guidance on revenue and profit for the current fiscal year. Estée Lauder sees sales rising 12.5 percent to 13.5 percent, up from a previous range of 10 percent to 11 percent.
By Jonathan Roeder in Chicago; editors: Nick Turner, Jonathan Roeder, Jessica Brice
This month, BoF Careers provides essential sector insights to help beauty professionals decode the industry’s creative landscape.
The skincare-to-smoothie pipeline arrives.
Puig and Space NK are cashing in on their ability to tap the growth of hot new products, while L’Occitane, Olaplex and The Estée Lauder Companies are discovering how quickly the shine can come off even the biggest brands.
Demand for the drugs has proven insatiable. Shortages have left patients already on the medications searching for their next dose and stymied new starters.